Drugs

, Volume 73, Issue 11, pp 1183–1196

Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion

Adis Drug Evaluation

Abstract

Lenalidomide (Revlimid®), a thalidomide analogue, is an orally administered second generation immunomodulator with anti-angiogenic, antineoplastic, anti-inflammatory and pro-erythropoietic properties. It is approved for the treatment of patients with transfusion-dependent anaemia due to International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with either chromosome 5q deletion [del(5q)] with or without additional cytogenetic abnormalities (US, Japan and Switzerland etc.), or with an isolated del(5q) cytogenetic abnormality when other therapeutic options are insufficient or inadequate (EU) [featured indication]. In a randomized, double-blind, multicentre, registrational trial (MDS-004; n = 205) in this patient population, a significantly higher proportion of lenalidomide recipients than placebo recipients achieved red blood cell transfusion independence for ≥26 consecutive weeks (primary endpoint for efficacy) and cytogenetic responses. The erythroid response to lenalidomide was accompanied by an increase in the haemoglobin levels. These efficacy outcomes are generally consistent with those seen in an earlier noncomparative registrational trial (MDS-003; n = 148). In MDS-004, lenalidomide also significantly improved health-related quality of life compared with placebo at 12 weeks. Retrospective analyses that compared outcomes between lenalidomide-treated patients with low- or intermediate-1-risk del(5q) MDS and multicentre registry cohorts showed that lenalidomide treatment did not appear to increase the risk of progression to acute myeloid leukaemia. Lenalidomide had a manageable safety profile in the registrational trials, with ≤20 % of patients discontinuing treatment because of adverse events. The most common adverse events (incidence ≥20 %) occurring in lenalidomide recipients were thrombocytopenia and neutropenia, which were generally managed by dosage reductions and/or interruptions, and/or pharmacotherapy. Thus, lenalidomide is a useful option for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk del(5q) MDS, with or without additional cytogenetic abnormalities.

References

  1. 1.
    Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83(1):71–86.PubMedGoogle Scholar
  2. 2.
    Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res. 2011;35(12):1591–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Bacher U, Schnittger S, Kern W, et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol. 2009;88(12):1207–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–95.PubMedCrossRefGoogle Scholar
  6. 6.
    Kantarjian H, O’Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115(22):5202–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168–78.PubMedGoogle Scholar
  8. 8.
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010;24(7):1283–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Padron E, Komrokji R, List AF. The 5q− syndrome: biology and treatment. Curr Treat Options Oncol. 2011;12(4):354–68.PubMedCrossRefGoogle Scholar
  12. 12.
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.PubMedGoogle Scholar
  13. 13.
    Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011;9(1):30–56.PubMedGoogle Scholar
  15. 15.
    Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26(6):1286–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71(5):625–49.PubMedCrossRefGoogle Scholar
  17. 17.
    Heise C, Carter T, Schafer P, et al. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010;10(10):1663–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;. doi:10.1186/1756-8722-2-36.PubMedGoogle Scholar
  19. 19.
    Boyer DF, Attar E, Hasserjian RP. Fli-1 expression is increased in erythroblasts in MDS with DEL(5Q) and correlates with response to lenalidomide [abstract no. 1366]. Lab Invest. 2012;92(S1):325A–6A.Google Scholar
  20. 20.
    Jonasova A, Fuchs O, Vostry M, et al. The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q− syndrome to lenalidomide treatment [abstract no. 274]. Leuk Res. 2011;35(Suppl. 1):S108.CrossRefGoogle Scholar
  21. 21.
    Buesche G, Giagounidis A, Gohring G, et al. Mechanisms of action of lenalidomide on erythroblastic islands in patients with low- or intermediate-1-risk MDS with del(5q) chromosome abnormality [abstract no. 269]. Leuk Res. 2011;35(Suppl. 1):S106.CrossRefGoogle Scholar
  22. 22.
    Ximeri M, Galanopoulos A, Klaus M, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95(3):406–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Belickova M, Cermak J, Dostalova Merkerova M, et al. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clin Lymphoma Myeloma Leuk. 2012;12(5):375–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2):e35.PubMedCrossRefGoogle Scholar
  25. 25.
    Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol. 2010;85(3):231–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Oliva EN, Cuzzola M, Aloe Spiriti MA, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol. 2013;92(1):25–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Venner CP, Woltosz JW, Nevill TJ, et al. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013;98(3):409–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Pellagatti A, Jadersten M, Forsblom A-M, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007;104(27):11406–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24(4):748–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA. 2009;106(31):12974–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025–37.PubMedCrossRefGoogle Scholar
  33. 33.
    Celgene Corporation. Revlimid® (lenalidomide) capsules product information. 2012. http://celgene.com.au/download/RevlimidPI.pdf. Accessed 30 April 2013.
  34. 34.
    Celgene Corporation. REVLIMID [lenalidomide] capsules, for oral use: prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021880s031lbl.pdf. Accessed 30 April 2013.
  35. 35.
    Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47(12):1466–75.PubMedCrossRefGoogle Scholar
  36. 36.
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–57.PubMedCrossRefGoogle Scholar
  37. 37.
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.PubMedCrossRefGoogle Scholar
  38. 38.
    Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–76.PubMedCrossRefGoogle Scholar
  39. 39.
    Fenaux P, Giagounidis A, Selleslag D, et al. Effect of baseline EPO and prior erythropoiesis stimulating agents on RBC transfusion independence in Low-/Int-1-risk MDS with del5q treated with lenalidomide: a randomized phase 3 study (MDS-004) [abstract no. 0311]. Haematologica. 2010;95(Suppl. 2):125.Google Scholar
  40. 40.
    Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Sekeres MA, Maciejewski JP, Giagounidis AAN, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26(36):5943–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Revicki DA, Brandenburg NA, Muus P, et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res. 2013;37(3):259–65.PubMedCrossRefGoogle Scholar
  43. 43.
    Fenaux P, Giagounidis A, List AF, et al. Outcomes for patients (Pts) with low-/int-1-risk myelodysplastic syndromes (MDS) with del5q aged <65 years treated with lenalidomide (LEN) in MDS-003 and MDS-004: a retrospective combined analysis [abstract no. 1723]. Blood. 2011;118(21).Google Scholar
  44. 44.
    Giagounidis A, Hellstrom-Lindberg E, Fenaux P, et al. Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients [abstract no. 58]. Leuk Res. 2011;35(Suppl. 1):S21.CrossRefGoogle Scholar
  45. 45.
    Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2012. doi:10.1038/leu.2012.369.PubMedGoogle Scholar
  46. 46.
    Buckstein R, Alibhai S, Lam A, et al. Transfusion dependence and low hemoglobin have the greatest impact on quality of life in MDS patients—a tertiary care cross sectional and longitudinal study [abstract no. 2500]. Blood. 2009;114(22).Google Scholar
  47. 47.
    Oliva EN, Latagliata R, Lagana C, et al. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma. 2013. doi:10.3109/10428194.2013.778406.
  48. 48.
    Sanchez-Garcia J, Del Canizo C, Such E, et al. A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion [abstract no. 64]. Leuk Res. 2011;35(Suppl. 1):S24.CrossRefGoogle Scholar
  49. 49.
    Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671–4.PubMedGoogle Scholar
  50. 50.
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Hellstrom-Lindberg E, Giagounidis A, Selleslag D, et al. Update on safety and long-term outcomes in lenalidomide (LEN)-treated patients with red blood cell (RBC) transfusion-dependent low-/int-1-risk myelodysplastic syndromes (MDS) and del(5q) [abstract no. 0870 plus poster 1715]. Haematologica. 2012;97(s1):358–9.Google Scholar
  52. 52.
    Sekeres MA. Lenalidomide in MDS: 4th time’s a charm. Blood. 2011;118(14):3757–8.PubMedCrossRefGoogle Scholar
  53. 53.
    European Medicines Agency. Withdrawal assessment report for lenalidomide Celgene Europe. 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500065821.pdf. Accessed 17 April 2013.
  54. 54.
    Ades L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012;97(2):213–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Gohring G, Lange K, Hofmann W, et al. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia. 2012;26(2):356–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Fenaux P, Giagounidis A, Selleslag DL, et al. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality [abstract no. 6598]. J Clin Oncol. 2010;28(15).Google Scholar
  57. 57.
    Giagounidis A, Raza A, List AF, et al. Analysis of second primary malignancies in lenalidomide-treated patients with IPSS low- or Int-1-risk myelodysplastic syndromes [abstract no. 1704]. Blood. 2011;118(21).Google Scholar
  58. 58.
    Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29(3):161–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Celgene Corporation. REVLIMID(R) granted Swissmedic approval for treatment of rare blood cancer [media release]. 21 Nov 2011. http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle_print&ID=1632356&highlight=.
  60. 60.
    Pharmaceuticals and Medical Devices Agency. Products Approved in FY 2010: New Drugs. 2010. http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2010.pdf. Accessed 21 Dec 2012.
  61. 61.
    European Medicines Agency. Revlimid (lenalidomide): summary of product characteristics. 2013. http://ec.europa.eu/health/documents/community-register/2013/20130613126109/anx_126109_en.pdf. Accessed 25 Jun 2013.
  62. 62.
    Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v158–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations